Skip to main content

Research Repository

Advanced Search

All Outputs (31)

Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening (2025)
Journal Article
Sullivan, F. M., Mair, F. S., Anderson, W., Chew, C., Dorward, A., Haughney, J., Hogarth, F., Kendrick, D., Littleford, R., McConnachie, A., McCowan, C., McMeekin, N., Patel, M., Rauchhaus, P., Daly, F., Ritchie, L., Robertson, J., Sarvesvaran, J., Sewell, H., Taylor, T., …Schembri, S. (2025). Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening. PLoS ONE, 20(1), Article e0306163. https://doi.org/10.1371/journal.pone.0306163

The role of biomarkers in risk-based early detection of lung cancer may enable screening to become cost effective and widely accessible. EarlyCDT-Lung is an example of such a blood-based autoantibody biomarker which may improve accessibility to Low d... Read More about Five year mortality in an RCT of a lung cancer biomarker to select people for low dose CT screening.

Optimisation of additively manufactured coiled flow inverters for continuous viral inactivation processes (2024)
Journal Article
Barrera, M. C., Leech, D., Josifovic, A., Tolouei, A., Alford, G., Wallace, M. J., Bennett, N., Wildman, R., Irvine, D. J., Croft, A., Özcan, E., Florence, A. J., Johnston, B., Robertson, J., & Brown, C. J. (2025). Optimisation of additively manufactured coiled flow inverters for continuous viral inactivation processes. Chemical Engineering Research and Design, 213, 126-136. https://doi.org/10.1016/j.cherd.2024.11.040

This article reports the development and utilisation of an adaptive design workflow methodology for use as a platform technology for the printing, testing, and optimisation of biopharmaceutical processing reactors. This design strategy was developed... Read More about Optimisation of additively manufactured coiled flow inverters for continuous viral inactivation processes.

Psychological impact of lung cancer screening using a novel antibody blood test followed by imaging: the ECLS randomised controlled trial (2022)
Journal Article
Hancox, J., Ayling, K., Bedford, L., Vedhara, K., Robertson, J. F. R., Young, B., das Nair, R., Sullivan, F. M., Schembri, S., Mair, F. S., Littleford, R., & Kendrick., D. (2023). Psychological impact of lung cancer screening using a novel antibody blood test followed by imaging: the ECLS randomised controlled trial. Journal of Public Health, 45(2), e275–e284. https://doi.org/10.1093/pubmed/fdac032

Background: The Early CDT®-Lung antibody blood test plus serial CT-scans for test-positives reduces late-stage lung cancer presentation. This study assessed psychological outcomes of this approach.

Methods: Randomised controlled trial (n=12,208) c... Read More about Psychological impact of lung cancer screening using a novel antibody blood test followed by imaging: the ECLS randomised controlled trial.

Meta-analyses of Phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer (2021)
Journal Article
Robertson, J. F., Paridaens, R. J., Lichfield, J., Bradbury, I., & Campbell, C. (2021). Meta-analyses of Phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer. European Journal of Cancer, 145, 19-28. https://doi.org/10.1016/j.ejca.2020.11.038

Background
Four randomised controlled trials (RCTs) in postmenopausal women with advanced breast cancer (ABC) comparing aromatase inhibitors (AIs) versus the selective estrogen receptor modulator tamoxifen, each individually reported significantly... Read More about Meta-analyses of Phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.

Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial (2020)
Journal Article
Smith, I., Robertson, J., Kilburn, L., Wilcox, M., Evans, A., Holcombe, C., Horgan, K., Kirwan, C., Mallon, E., Sibbering, M., Skene, A., Vidya, R., Cheang, M., Banerji, J., Morden, J., Sidhu, K., Dodson, A., Bliss, J. M., & Dowsett, M. (2020). Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncology, 21(11), 1443-1454. https://doi.org/10.1016/S1470-2045%2820%2930458-7

Background: Preoperative and perioperative aromatase inhibitor (POAI) therapy has the potential to improve outcomes in women with operable oestrogen receptor-positive primary breast cancer. It has also been suggested that tumour Ki67 values after 2 w... Read More about Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial.

Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance (2020)
Journal Article
Campbell, C., Mathew, J., Ellis, I. O., Bradbury, I., Borgquist, S., Elebro, K., Green, A. R., Finlay, P., Gee, J. M. W., & Robertson, J. F. R. (2020). Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance. Translational Breast Cancer Research, 1, Article 29. https://doi.org/10.21037/tbcr-20-31

Background: It remains clinically important to identify ER positive breast cancers likely to respond to tamoxifen (TAM) and so we aimed to select a group of biomarkers able to predict response. We also assessed whether data from different sample type... Read More about Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance.

The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ (2020)
Journal Article
Miligy, I. M., Toss, M. S., Shiino, S., Oni, G., Syed, B. M., Khout, H., Tan, Q., Green, A. R., Macmillan, R. D., Robertson, J. F. R., & Rakha, E. A. (2020). The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. British Journal of Cancer, 123(10), 1513-1520. https://doi.org/10.1038/s41416-020-1023-3

Background: Oestrogen receptor (ER) in invasive breast cancer (BC) predicts response to endocrine therapy (ET) and provides prognostic value. In this study, we investigated the value of ER expression in ductal carcinoma in situ (DCIS) in terms of out... Read More about The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ.

Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging (2020)
Journal Article
Sullivan, F. M., Mair, F. S., Anderson, W., Armory, P., Briggs, A., Chew, C., Dorward, A., Haughney, J., Hogarth, F., Kendrick, D., Littleford, R., McConnachie, A., McCowan, C., Mcmeekin, N., Patel, M., Rauchhaus, P., Ritchie, L., Robertson, C., Robertson, J., Robles-Zurita, J., …Schembri, S. (2021). Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. European Respiratory Journal, 57(1), Article 2000670. https://doi.org/10.1183/13993003.00670-2020

The EarlyCDT-Lung test is a high specificity blood-based autoantibody biomarker that could contribute to predicting lung cancer risk. Here we report on the results of a phase IV biomarker evaluation of whether using the EarlyCDT-Lung test and any sub... Read More about Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.

Improving primary care identification of familial breast cancer risk using proactive invitation and decision support (2020)
Journal Article
Qureshi, N., Dutton, B., Weng, S., Sheehan, C., Chorley, W., Robertson, J. F., Kendrick, D., & Kai, J. (2021). Improving primary care identification of familial breast cancer risk using proactive invitation and decision support. Familial Cancer, 20(1), 13-21. https://doi.org/10.1007/s10689-020-00188-z

Family history of breast cancer is a key risk factor, accounting for up to 10% of cancers. We evaluated the proactive assessment of familial breast cancer (FBC) risk in primary care. Eligible women (30 to 60 years) were recruited from eight English g... Read More about Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.

A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer (2020)
Journal Article
Robertson, J. F., Evans, A., Henschen, S., Kirwan, C. C., Jahan, A., Kenny, L. M., Dixon, J. M., Schmid, P., Kothari, A., Mohamed, O., Fasching, P. A., Cheung, K. L., Wuerstlein, R., Carroll, D., Klinowska, T., Lindemann, J. P., MacDonald, A., Mather, R., Maudsley, R., Moschetta, M., …Harbeck, N. (2020). A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer. Clinical Cancer Research, 26(16), 4242-4249. https://doi.org/10.1158/1078-0432.CCR-19-3387

©2020 American Association for Cancer Research. PURPOSE: Fulvestrant, the first-in-class selective estrogen receptor (ER) degrader (SERD), is clinically effective in patients with ER+ breast cancer, but it has administration and pharmacokinetic limit... Read More about A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.

Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT) (2019)
Journal Article
Young, B., Bedford, L., das Nair, R., Gallant, S., Littleford, R., Robertson, J. F., Schembri, S., Sullivan, F. M., Vedhara, K., Kendrick, D., & ECLS Study Team. (2020). Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT). Journal of Evaluation in Clinical Practice, 26(3), 893-902. https://doi.org/10.1111/jep.13230

Rationale, aims, and objectives: High response rates to research questionnaires can help to ensure results are more representative of the population studied and provide increased statistical power, on which the study may have been predicated. Improvi... Read More about Unconditional and conditional monetary incentives to increase response to mailed questionnaires: A randomized controlled study within a trial (SWAT).

A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening (2019)
Presentation / Conference Contribution
Figueredo, G. P., Shi, P., Parkes, A. J., Evans, K., Garibaldi, J. M., Negm, O., Tighe, P. J., Sewell, H. F., & Robertson, J. (2019, June). A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening. Presented at 2019 IEEE Congress on Evolutionary Computation (CEC), Wellington, New Zealand

Current methods to identify cutoff values for tumour-associated molecules (antigens) discrimination are based on statistics and brute force. These methods applied to cancer screening problems are very inefficient, especially with large data sets with... Read More about A Hybrid Evolutionary Strategy to Optimise Early-Stage Cancer Screening.

A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer (2019)
Journal Article
Robertson, J. F. R., Jiang, Z., Di Leo, A., Ohno, S., Pritchard, K. I., Ellis, M., Bradbury, I., & Campbell, C. (2019). A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer, 26(6), 703-711. https://doi.org/10.1007/s12282-019-00973-4

Background
Fulvestrant, a selective estrogen receptor degrader, is approved for first- and second-line treatment of postmenopausal women with hormone receptor-positive advanced breast cancer (ABC).

Methods
Meta-analysis of randomized controlled... Read More about A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.

Determinants of motivation to quit in smokers screened for the early detection of lung cancer: a qualitative study (2018)
Journal Article
Young, B., Vedhara, K., Kendrick, D., Littleford, R., Robertson, J. F. R., Sullivan, F. M., Schembri, S., das Nair, R., & in collaboration with the ECLS study team. (2018). Determinants of motivation to quit in smokers screened for the early detection of lung cancer: a qualitative study. BMC Public Health, 18(1), Article 1276. https://doi.org/10.1186/s12889-018-6211-1

Background: The promotion of smoking cessation within lung cancer screening could lead to benefits for smoking-related disease and improve cost-effectiveness of screening. Little is known about how smokers respond to lung cancer screening and how thi... Read More about Determinants of motivation to quit in smokers screened for the early detection of lung cancer: a qualitative study.

Lung cancer screening: does pulmonary nodule detection affect a range of smoking behaviours? (2018)
Journal Article
Clark, M. E., Young, B., Bedford, L. E., Robertson, J. F., das Nair, R., Vedhara, K., Sullivan, F., Mair, F. S., Schembri, S., Littleford, R. C., & Kendrick, D. (2019). Lung cancer screening: does pulmonary nodule detection affect a range of smoking behaviours?. Journal of Public Health, 41(3), 600-608. https://doi.org/10.1093/pubmed/fdy158

Background
Lung cancer screening can reduce lung cancer mortality by 20%. Screen-detected abnormalities may provide teachable moments for smoking cessation. This study assesses impact of pulmonary nodule detection on smoking behaviours within the fi... Read More about Lung cancer screening: does pulmonary nodule detection affect a range of smoking behaviours?.

Lung cancer CT screening: psychological responses in the presence and absence of pulmonary nodules (2018)
Journal Article
Clark, M. E., Bedford, L. E., Young, B., Robertson, J. F., das Nair, R., Vedhara, K., Littleford, R., Sullivan, F. M., Mair, F. S., Schembri, S., Rauchhaus, P., & Kendrick, D. (2018). Lung cancer CT screening: psychological responses in the presence and absence of pulmonary nodules. Lung Cancer, 124, 160-167. https://doi.org/10.1016/j.lungcan.2018.08.001

Objectives: To determine the psychological response (thoughts, perceptions and affect) to a diagnosis of pulmonary nodules following a novel antibody blood test and computed tomography (CT) scans within a UK population.

Materials and methods: This... Read More about Lung cancer CT screening: psychological responses in the presence and absence of pulmonary nodules.

Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer (2018)
Journal Article
Robertson, J. F., Cheung, K.-L., Noguchi, S., Shao, Z., Degboe, A., Lichfield, J., Thirlwell, J., Fazal, M., & Ellis, M. J. (2018). Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer. European Journal of Cancer, 94, https://doi.org/10.1016/j.ejca.2018.02.026

Background
The phase III randomised FALCON trial (NCT01602380) demonstrated improved progression-free survival with fulvestrant 500 mg versus anastrozole 1 mg in endocrine therapy-naïve postmenopausal women with hormone receptor-positive (HR+) local... Read More about Health-related quality of life from the FALCON phase III randomised trial of fulvestrant 500 mg versus anastrozole for hormone receptor-positive advanced breast cancer.